➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
Colorcon
Boehringer Ingelheim
Baxter
McKesson

Last Updated: May 13, 2021

DrugPatentWatch Database Preview

COZAAR Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Cozaar patents expire, and what generic alternatives are available?

Cozaar is a drug marketed by Organon and is included in one NDA.

The generic ingredient in COZAAR is losartan potassium. There are thirty-nine drug master file entries for this compound. Fifty-one suppliers are listed for this compound. Additional details are available on the losartan potassium profile page.

Drug patent expirations by year for COZAAR
Drug Prices for COZAAR

See drug prices for COZAAR

Drug Sales Revenue Trends for COZAAR

See drug sales revenues for COZAAR

Recent Clinical Trials for COZAAR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Flight Attendant Medical Research InstitutePhase 4
University of California, San FranciscoPhase 4
Oregon Health and Science UniversityPhase 2

See all COZAAR clinical trials

Pharmacology for COZAAR
Paragraph IV (Patent) Challenges for COZAAR
Tradename Dosage Ingredient NDA Submissiondate
COZAAR TABLET;ORAL losartan potassium 020386

US Patents and Regulatory Information for COZAAR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Organon COZAAR losartan potassium TABLET;ORAL 020386-001 Apr 14, 1995 DISCN Yes No   Get Started for $10   Get Started for $10   Get Started for $10
Organon COZAAR losartan potassium TABLET;ORAL 020386-002 Apr 14, 1995 DISCN Yes No   Get Started for $10   Get Started for $10   Get Started for $10
Organon COZAAR losartan potassium TABLET;ORAL 020386-003 Oct 13, 1998 AB RX Yes Yes   Get Started for $10   Get Started for $10   Get Started for $10
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for COZAAR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Organon COZAAR losartan potassium TABLET;ORAL 020386-002 Apr 14, 1995   Get Started for $10   Get Started for $10
Organon COZAAR losartan potassium TABLET;ORAL 020386-001 Apr 14, 1995   Get Started for $10   Get Started for $10
Organon COZAAR losartan potassium TABLET;ORAL 020386-001 Apr 14, 1995   Get Started for $10   Get Started for $10
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for COZAAR

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0253310 C950009 Netherlands   Get Started for $10 PRODUCT NAME: LOSARTAN, DESGEWENST IN DE VORM VAN EEN AANVAARDBAAR ZOUT, IN HET BIJZONDER HET KALIUMZOUT; NAT. REGISTRATION NO/DATE: RVG 17617 19950314; FIRST REGISTRATION: SE 12209 19940902
0733366 SPC/GB98/031 United Kingdom   Get Started for $10 PRODUCT NAME: 2-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL) BIPHENYL-4-YL)-METHYL)-5-(HYDROXYMETHYL)IMIDAZOLE (LOSARTAN),OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT( LOSARTAN POTASSIUM) AND HYDROCHLOROTHIAZIDE,; REGISTERED: FR 338520.7 19950215; FR 558453.7 19950215; UK 00025/0338 19960412
0253310 SPC/GB95/010 United Kingdom   Get Started for $10 PRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Baxter
Colorcon
McKesson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.